FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Klaus Jung

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Anatomy

Prostate

Physiology

Gene Expression Regulation, Neoplastic

Procedures

Co-author Network

Publications

TOP 3
Xinhai Hu; Klaus Jung; Hellmuth-Alexander Meyer; Kurt Miller; Henning Cammann; Carsten Stephan
Artificial neural networks and prostate cancer--tools for diagnosis and management.
Juan R Rodrigues; Arthur Barazarte; José Camacho; Jaime Charris; Neira Gamboa; Michael Höpfner; Klaus Jung; Michael Lein; Bianca Nitzsche; Claudia Abramjuk
N'-Formyl-2-(5-nitrothiophen-2-yl)benzothiazole-6-carbohydrazide as a potential anti-tumour agent for prostate cancer in experimental studies.
Zofia Wotschofsky; Jonas Busch; Andreas Erbersdobler; Monika Jung; Carsten Kempkensteffen; Ergin Kilic; Glen Kristiansen; Ingo Melcher; Kurt Miller; Klaus D Schaser; Steffen Weikert; Klaus Jung
Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Klaus Jung (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Xinhai Hu; Klaus Jung; Hellmuth-Alexander Meyer; Kurt Miller; Henning Cammann; Carsten Stephan
Artificial neural networks and prostate cancer--tools for diagnosis and management.
Nature reviews. Urology 2013;10(3):174-82.
2013: Juan R Rodrigues; Arthur Barazarte; José Camacho; Jaime Charris; Neira Gamboa; Michael Höpfner; Klaus Jung; Michael Lein; Bianca Nitzsche; Claudia Abramjuk
N'-Formyl-2-(5-nitrothiophen-2-yl)benzothiazole-6-carbohydrazide as a potential anti-tumour agent for prostate cancer in experimental studies.
The Journal of pharmacy and pharmacology 2013;65(3):411-22.
2013: Zofia Wotschofsky; Jonas Busch; Andreas Erbersdobler; Monika Jung; Carsten Kempkensteffen; Ergin Kilic; Glen Kristiansen; Ingo Melcher; Kurt Miller; Klaus D Schaser; Steffen Weikert; Klaus Jung
Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy.
Clinica chimica acta; international journal of clinical chemistry 2013;416():5-10.
2013: Annika Fendler; Klaus Jung
MicroRNAs as New Diagnostic and Prognostic Biomarkers in Urological Tumors.
Critical reviews in oncogenesis 2013;18(4):289-302.
2013: Carsten Stephan; Sébastien Vincendeau; Henning Cammann; Alain Houlgatte; Klaus Jung; Axel Semjonow
Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.
Clinical chemistry 2013;59(1):306-14.
2013: Carsten Stephan; Martin Bögemann; Henning Cammann; Xinhai Hu; Klaus Jung; Hellmuth-Alexander Meyer; Kurt Miller; Kai Schulze-Forster; Axel Semjonow; Frank Friedersdorff
Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
Clinical chemistry 2013;59(1):280-8.
2013: Carsten Stephan; Klaus Jung
TMPRSS2-ERG fusion transcripts in matched urine and needle rinse material after biopsy for the detection of prostate cancer: really a step forward?
Clinical chemistry 2013;59(1):9-10.
2013: Klaus Jung
A review of expression profiling of circulating microRNAs in men with prostate cancer.
BJU international 2013;111(1):3-4.
2012: Jonas Busch; Kristin Hamborg; Klaus Jung; Michael Lein; Ahmed Magheli; Hellmuth-Alexander Meyer; Kurt Miller; John Buckendahl; Carsten Stephan
Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosis.
The Journal of urology 2012;188(6):2165-70.
2012: Juan R Rodrigues; Jorge Angel; Jaime Charris; Rosa Ferrer; Neira Gamboa; Michael Hoepfner; Klaus Jung; Michael Lein; Bianca Nitzsche; Claudia Abramjuk
Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo.
Investigational new drugs 2012;30(4):1426-33.
2012: Anja Rabien; Andreas Erbersdobler; Bettina Ergün; Klaus Jung; Carsten Stephan
RECK overexpression decreases invasive potential in prostate cancer cells.
The Prostate 2012;72(9):948-54.
2012: Michael Knösel; Mariana Bojes; Klaus Jung; Dirk Ziebolz
Increased susceptibility for white spot lesions by surplus orthodontic etching exceeding bracket base area.
American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 2012;141(5):574-82.
2012: Julia Liep; Anja Rabien; Klaus Jung
Feedback networks between microRNAs and epigenetic modifications in urological tumors.
Epigenetics : official journal of the DNA Methylation Society 2012;7(4):315-25.
2012: Isabel Steiner; Carsten Stephan; Klaus Jung; Kurt Miller; Andreas Erbersdobler
Expression of endothelial factors in prostate cancer: a possible role of caveolin-1 for tumour progression.
Oncology reports 2012;27(2):389-95.
2012: Zofia Wotschofsky; Jonas Busch; Alexander C Disch; Andreas Erbersdobler; Monika Jung; Ergin Kilic; Julia Liep; Ingo Melcher; Hellmuth-Alexander Meyer; Kurt Miller; Hans-Joachim Mollenkopf; Klaus-Dieter Schaser; Ina Wagner; Steffen Weikert; Klaus Jung
Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas.
International journal of biological sciences 2012;8(10):1363-74.
2012: Hellmuth-Alexander Meyer; Thomas Behrends; Tobias Endermann; Klaus Jung; Carsten Stephan; Mette Stoedter; Ingmar Wolff; Lutz Schomburg
Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients.
PloS one 2012;7(10):e46644.
2012: Nadine Ratert; Ina Wagner; Steffen Weikert; Andreas Erbersdobler; Monika Jung; Ergin Kilic; Hellmuth-Alexander Meyer; Kurt Miller; Hans-Joachim Mollenkopf; Klaus Jung
Reference miRNAs for miRNAome analysis of urothelial carcinomas.
PloS one 2012;7(6):e39309.
2011: Carsten Stephan; Kurt Miller; Klaus Jung
Is there an optimal prostate-specific antigen threshold for prostate biopsy?
Expert review of anticancer therapy 2011;11(8):1215-21.
2011: Annika Fendler; Carsten Stephan; George M Yousef; Klaus Jung
MicroRNAs as regulators of signal transduction in urological tumors.
Clinical chemistry 2011;57(7):954-68.
2011: Carsten Stephan; Kurt Miller; Mark Schrader; Kerstin Siemssen; Henning Cammann; Serdar Deger; Frank Friedersdorff; Klaus Jung; Michael Lein; Hellmuth-Alexander Meyer
Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms.
Clinical chemistry 2011;57(7):995-1004.
2011: Angelika Tölle; Hans Krause; Kurt Miller; Klaus Jung; Carsten Stephan
Importance of brain‑type fatty acid binding protein for cell-biological processes in human renal carcinoma cells.
Oncology reports 2011;25(5):1307-12.
2011: Klaus Jung; Kurt Miller; Manfred Wirth; Michael Albrecht; Michael Lein
Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid.
European urology 2011;59(4):604-12.
2011: Juan Rodrigues; Claudia Abramjuk; Luis Vásquez; Neira Gamboa; José Domínguez; Bianca Nitzsche; Michael Höpfner; Radostina Georgieva; Hans Bäumler; Carsten Stephan; Klaus Jung; Michael Lein; Anja Rabien
New 4-maleamic acid and 4-maleamide peptidyl chalcones as potential multitarget drugs for human prostate cancer.
Pharmaceutical research 2011;28(4):907-19.
2011: Florian Jentzmik; Carsten Stephan; Michael Lein; Kurt Miller; Beate Kamlage; Bianca Bethan; Glen Kristiansen; Klaus Jung
Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression.
The Journal of urology 2011;185(2):706-11.
2011: Angelika Tölle; Saba Suhail; Klaus Jung; Monika Jung; Carsten Stephan
Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma.
BMC cancer 2011;11():302.
2011: Daniel Wittschieber; Albrecht Stenzinger; Carsten Stephan; Andreas Erbersdobler; Klaus Jung; Frederick Klauschen; Anja Rabien
Decreased RECK and Increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness.
Pathobiology : journal of immunopathology, molecular and cellular biology 2011;78(3):123-31.
2011: Gareth Catchpole; Alexander Platzer; Cornelia Weikert; Carsten Kempkensteffen; Manfred Johannsen; Hans Krause; Klaus Jung; Kurt Miller; Lothar Willmitzer; Joachim Selbig; Steffen Weikert
Metabolic profiling reveals key metabolic features of renal cell carcinoma.
Journal of cellular and molecular medicine 2011;15(1):109-18.
2010: Annika Schaefer; Monika Jung; Kurt Miller; Michael Lein; Glen Kristiansen; Andreas Erbersdobler; Klaus Jung
Suitable reference genes for relative quantification of miRNA expression in prostate cancer.
Experimental & molecular medicine 2010;42(11):749-58.
2010: Anja Rabien; Florian R Fritzsche; Monika Jung; Angelika Tölle; Eleftherios P Diamandis; Kurt Miller; Klaus Jung; Glen Kristiansen; Carsten Stephan
KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
International journal of cancer. Journal international du cancer 2010;127(10):2386-94.
2010: Klaus Jung; Michael Fleischhacker; Anja Rabien
Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature.
Clinica chimica acta; international journal of clinical chemistry 2010;411(21-22):1611-24.
2010: Florian Jentzmik; Carsten Stephan; Kurt Miller; Mark Schrader; Andreas Erbersdobler; Glen Kristiansen; Michael Lein; Klaus Jung
Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours.
European urology 2010;58(1):12-8; discussion 20-1.
2010: Monika Jung; Annika Schaefer; Isabel Steiner; Carsten Kempkensteffen; Carsten Stephan; Andreas Erbersdobler; Klaus Jung
Robust microRNA stability in degraded RNA preparations from human tissue and cell samples.
Clinical chemistry 2010;56(6):998-1006.
2010: Florian R Fritzsche; Carsten Stephan; Josefine Gerhardt; Michael Lein; Irina Hofmann; Klaus Jung; Manfred Dietel; Glen Kristiansen
Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in prostate cancer.
Histology and histopathology 2010;25(6):733-9.
2010: Annika Schaefer; Klaus Jung
Re: MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
European urology 2010;57(5):919.
2010: Verena Tischler; Florian R Fritzsche; Josefine Gerhardt; Christian Jäger; Carsten Stephan; Klaus Jung; Manfred Dietel; Holger Moch; Glen Kristiansen
Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker.
Histopathology 2010;56(6):811-5.
2010: Angelika Tölle; Ziyad Abdallah; Klaus Jung; Hans Bäumler
Measurement conditions for flow cytometry analyses of cell lines from urological carcinomas.
Journal of fluorescence 2010;20(3):779-86.
2010: Isabel Steiner; Klaus Jung; Philipp Schatz; Torsten Horns; Daniel Wittschieber; Michael Lein; Manfred Dietel; Andreas Erbersdobler
Gene promoter methylation and its potential relevance in early prostate cancer diagnosis.
Pathobiology : journal of immunopathology, molecular and cellular biology 2010;77(5):260-6.
2010: Verena Tischler; Florian R Fritzsche; Peter J Wild; Carsten Stephan; Hans-Helge Seifert; Marc-Oliver Riener; Thomas Hermanns; Ashkan Mortezavi; Josefine Gerhardt; Peter Schraml; Klaus Jung; Holger Moch; Alex Soltermann; Glen Kristiansen
Periostin is up-regulated in high grade and high stage prostate cancer.
BMC cancer 2010;10():273.
2010: Carsten Stephan; Henning Cammann; Martin Bender; Kurt Miller; Michael Lein; Klaus Jung; Hellmuth-A Meyer
Internal validation of an artificial neural network for prostate biopsy outcome.
International journal of urology : official journal of the Japanese Urological Association 2010;17(1):62-8.
2010: Ahmed Magheli; Stefan Hinz; Claudia Hege; Carsten Stephan; Klaus Jung; Kurt Miller; Michael Lein
Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience.
The Journal of urology 2010;183(1):126-31.
2010: Annika Schaefer; Monika Jung; Glen Kristiansen; Michael Lein; Mark Schrader; Kurt Miller; Carsten Stephan; Klaus Jung
MicroRNAs and cancer: current state and future perspectives in urologic oncology.
Urologic oncology 2010;28(1):4-13.
2009: Carsten Stephan; Henning Cammann; Serdar Deger; Mark Schrader; Hellmuth-Alexander Meyer; Kurt Miller; Michael Lein; Klaus Jung
Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
Urology 2009;74(4):873-7.
2009: Monika Jung; Hans-Joachim Mollenkopf; Christina Grimm; Ina Wagner; Marco Albrecht; Tobias Waller; Christian Pilarsky; Manfred Johannsen; Carsten Stephan; Hans Lehrach; Wilfried Nietfeld; Thomas Rudel; Klaus Jung; Glen Kristiansen
MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy.
Journal of cellular and molecular medicine 2009;13(9B):3918-28.
2009: Claudia Abramjuk; Michael Bueschges; Jörg Schnorr; Klaus Jung; Andrea Staack; Michael Lein
Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo.
Oncology reports 2009;22(2):409-14.
2009: Carsten Stephan; Harry Rittenhouse; Henning Cammann; Michael Lein; Mark Schrader; Serdar Deger; Kurt Miller; Klaus Jung
New markers and multivariate models for prostate cancer detection.
Anticancer research 2009;29(7):2589-600.
2009: Michael Lein; Kurt Miller; Manfred Wirth; Lothar Weissbach; Christoph May; Katja Schmidt; Ulrike Haus; Mark Schrader; Klaus Jung
Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid.
The Prostate 2009;69(6):624-32.
2009: Carsten Stephan; Chris Bangma; Giulio Vignati; Georg Bartsch; Michael Lein; Klaus Jung; Marianne Philippe; Axel Semjonow; William J Catalona
20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers.
The International journal of biological markers 2009;24(2):65-9.
2009: Paul Gutwein; Anja Schramme; Nina Sinke; Mohamed Sadek Abdel-Bakky; Beren Voss; Nicholas Obermüller; Kai Doberstein; Michael Koziolek; Florian Fritzsche; Manfred Johannsen; Klaus Jung; Helmut Schaider; Peter Altevogt; Andreas Ludwig; Josef Pfeilschifter; Glen Kristiansen
Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients.
European journal of cancer (Oxford, England : 1990) 2009;45(3):478-89.
2009: Carsten Stephan; Anna-Maria Kahrs; Henning Cammann; Michael Lein; Mark Schrader; Serdar Deger; Kurt Miller; Klaus Jung
A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.
The Prostate 2009;69(2):198-207.
2009: Klaus Jung; Ferdinando Mannello; Michael Lein
Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles.
Journal of translational medicine 2009;7():87.
2009: Carsten Stephan; Thomas Köpke; Axel Semjonow; Michael Lein; Serdar Deger; Mark Schrader; Kurt Miller; Klaus Jung
Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?
Clinical chemistry and laboratory medicine : CCLM / FESCC 2009;47(11):1325-31.
2009: Carsten Kempkensteffen; Florian Rudolf Fritzsche; Manfred Johannsen; Steffen Weikert; Stefan Hinz; Manfred Dietel; Marc-Oliver Riener; Holger Moch; Klaus Jung; Hans Krause; Kurt Miller; Glen Kristiansen
Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer.
BMC cancer 2009;9():276.
2009: Angelika Tölle; Monika Jung; Michael Lein; Manfred Johannsen; Kurt Miller; Holger Moch; Klaus Jung; Glen Kristiansen
Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
BMC cancer 2009;9():248.
2009: Mark Schrader; Carsten Kempkensteffen; Frank Christoph; Stefan Hinz; Steffen Weikert; Michael Lein; Hans Krause; Carsten Stephan; Klaus Jung; Michael Hoepfner; Peter Albers; Kurt Miller; Martin Schostak
Germ cell tumors of the gonads: a selective review emphasizing problems in drug resistance and current therapy options.
Oncology 2009;76(2):77-84.
2009: Klaus Jung; Michael Lein
By mistakes we learn: determination of matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 in serum yields doubtful results.
Journal of clinical periodontology 2009;36(1):34-5; author reply 36-8.
2008: Klaus Jung
Measurement of matrix metalloproteinases and their tissue inhibitors in serum produces doubtful results.
The Journal of infectious diseases 2008;198(11):1722-3; author reply 1723-4.
2008: Ferdinando Mannello; Klaus Jung; Gaetana A M Tonti; Franco Canestrari
Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood.
Clinical biochemistry 2008;41(18):1466-73.
2008: Klaus Jung
Words of wisdom. Re: the metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions.
European urology 2008;54(5):1198-9.
2008: Florian R Fritzsche; Beibei Oelrich; Manfred Johannsen; Ilka Kristiansen; Holger Moch; Klaus Jung; Glen Kristiansen
Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):7035-42.
2008: Klaus Jung; Azizbek Ramankulov; Mark Schrader; Kurt Miller; Michael Lein
Circulating matrix metalloproteinase-7: an early or metastatic marker for renal cell carcinoma?
Clinical chemistry 2008;54(11):1927-9.
2008: Florian R Fritzsche; Monika Jung; Angelika Tölle; Peter Wild; Arndt Hartmann; Kirsten Wassermann; Anja Rabien; Michael Lein; Manfred Dietel; Christian Pilarsky; Daniela Calvano; Robert Grützmann; Klaus Jung; Glen Kristiansen
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
European urology 2008;54(5):1097-106.
2008: Carsten Stephan; Klaus Jung; Michael Lein; Serdar Deger
Re: Al-Azab R, Toi A, Lockwood G, et al. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL (Urology 69:103-107, 2007).
Urology 2008;72(4):951.
2008: Azizbek Ramankulov; Michael Lein; Manfred Johannsen; Mark Schrader; Kurt Miller; Stefan A Loening; Klaus Jung
Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma.
Cancer letters 2008;269(1):85-92.
2008: G Kristiansen; F R Fritzsche; K Wassermann; C Jäger; A Tölls; M Lein; C Stephan; Klaus Jung; C Pilarsky; M Dietel; H Moch
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.
British journal of cancer 2008;99(6):939-48.
2008: Carsten Stephan; Henning Cammann; Hellmuth-Alexander Meyer; Christian Müller; Serdar Deger; Michael Lein; Klaus Jung
An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics.
BJU international 2008;102(7):799-805.
2008: Klaus Jung
A strong note of caution in using matrix metalloproteinase-1 and its inhibitor, TIMP-1 in serum as biomarkers in systolic heart failure.
Journal of internal medicine 2008;264(3):291-3.
2008: Klaus Jung
Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy.
British journal of cancer 2008;99(3):553-4; author reply 555.
2008: Ferdinando Mannello; Klaus Jung
Blood sampling affects circulating TIMP-1 concentration, a useful biomarker in estimating liver fibrosis stages.
Hepatology (Baltimore, Md.) 2008;48(2):688-9; author reply 689-90.
2008: Florian Rudolf Fritzsche; Kirsten Wassermann; Anja Rabien; Hanka Schicktanz; Anja Dankof; Stefan A Loening; Manfred Dietel; Klaus Jung; Glen Kristiansen
CD146 protein in prostate cancer: revisited with two different antibodies.
Pathology 2008;40(5):457-64.
2008: Girish Sardana; Klaus Jung; Carsten Stephan; Eleftherios P Diamandis
Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Journal of proteome research 2008;7(8):3329-38.
2008: Carsten Stephan; Klaus Jung
Editorial comment on: diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter.
European urology 2008;54(2):369-70.
2008: Azizbek Ramankulov; Michael Lein; Manfred Johannsen; Mark Schrader; Kurt Miller; Klaus Jung
Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.
Cancer science 2008;99(6):1188-94.
2008: Klaus Jung
Serum samples are inappropriate for use in measuring circulating matrix metalloproteinases: comment on the article by Young-Min et al.
Arthritis and rheumatism 2008;58(5):1557-8; author reply 1559.
2008: Carsten Stephan; Henning Cammann; Michael Lein; Kurt Miller; Klaus Jung
Re: Application of artificial intelligence to the management of urological cancer. M. F. Abbod, J. W. Catto, D. A. Linkens and F. C. Hamdy J Urol 2007; 178: 1150-1156.
The Journal of urology 2008;179(5):2067.
2008: Klaus Jung
Matrix metalloproteinases do not properly work as peripheral blood biomarkers without taking into account the preanalytical impact of blood sampling.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2008;33(5):944; author reply 945.
2008: Klaus Jung; Silke Klotzek; Carsten Stephan; Ferdinando Mannello; Michael Lein
Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9.
Clinical chemistry 2008;54(4):772-3.
2008: Klaus Jung
Blood sampling and the measurement of circulating matrix metalloproteinase-8.
Clinica chimica acta; international journal of clinical chemistry 2008;390(1-2):156-7, author reply 158.
2008: Florian R Fritzsche; B Oelrich; Manfred Dietel; Klaus Jung; Glen Kristiansen
European and US publications in the 50 highest ranking pathology journals from 2000 to 2006.
Journal of clinical pathology 2008;61(4):474-81.
2008: Klaus Jung
Matrix metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in serum do not reflect the analytes circulating in blood.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(3):e15-6; author reply e17.
2008: Wilko Weichert; A Röske; Volker Gekeler; Thomas Beckers; Carsten Stephan; Klaus Jung; Florian R Fritzsche; Silvia Niesporek; Carsten Denkert; Manfred Dietel; Glen Kristiansen
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.
British journal of cancer 2008;98(3):604-10.
2008: Silvia Niesporek; Glen Kristiansen; Andrea Thoma; Wilko Weichert; Aurelia Noske; Ann-Christin Buckendahl; Klaus Jung; Carsten Stephan; Manfred Dietel; Carsten Denkert
Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression.
International journal of oncology 2008;32(2):341-7.
2008: Florian R Fritzsche; Wilko Weichert; Annika Röske; Volker Gekeler; Thomas Beckers; Carsten Stephan; Klaus Jung; Katharina Scholman; Carsten Denkert; Manfred Dietel; Glen Kristiansen
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.
BMC cancer 2008;8():381.
2008: Florian Rudolf Fritzsche; Mark-Oliver Riener; Manfred Dietel; Holger Moch; Klaus Jung; Glen Kristiansen
GOLPH2 expression in renal cell cancer.
BMC urology 2008;8():15.
2008: Carsten Stephan; Anna-Maria Kahrs; Silke Klotzek; Janett Reiche; Christian Müller; Michael Lein; Serdar Deger; Kurt Miller; Klaus Jung
Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2008;46(5):623-9.
2008: Carsten Stephan; Nicola Büker; Henning Cammann; Hellmuth-Alexander Meyer; Michael Lein; Klaus Jung
Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity.
BMC urology 2008;8():10.
2008: Florian R Fritzsche; Kirsten Wassermann; Monika Jung; Angelika Tölle; Ilka Kristiansen; Michael Lein; Manfred Johannsen; Manfred Dietel; Klaus Jung; Glen Kristiansen
ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression.
BMC cancer 2008;8():179.
2008: Anja Rabien; Florian R Fritzsche; Monika Jung; Eleftherios P Diamandis; Stefan A Loening; Manfred Dietel; Klaus Jung; Carsten Stephan; Glen Kristiansen
High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2008;29(1):1-8.
2007: Michael Lein; Manfred Wirth; Kurt Miller; Hans-Udo Eickenberg; Lothar Weissbach; Katja Schmidt; Ulrike Haus; Carsten Stephan; Sven Meissner; Stefan A Loening; Klaus Jung
Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
European urology 2007;52(5):1381-7.
2007: Beibei Oelrich; Robert Peters; Klaus Jung
A bibliometric evaluation of publications in urological journals among European Union countries between 2000-2005.
European urology 2007;52(4):1238-48.
2007: Carsten Stephan; Klaus Jung; Michael Lein; Eleftherios P Diamandis
PSA and other tissue kallikreins for prostate cancer detection.
European journal of cancer (Oxford, England : 1990) 2007;43(13):1918-26.
2007: Carsten Stephan; Chuanliang Xu; Patrik Finne; Henning Cammann; Hellmuth-Alexander Meyer; Michael Lein; Klaus Jung; Ulf-Hakan Stenman
Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations.
Urology 2007;70(3):596-601.
2007: Carsten Stephan; Klaus Jung; Henning Cammann; J Kramer; Glen Kristiansen; Stefan A Loening; Michael Lein
[New serum markers in prostate carcinoma and their application to artificial neural networks].
Der Urologe. Ausg. A 2007;46(9):1084-6.
2007: Anja Rabien; Monika Jung; Florian R Fritzsche; Stefan A Loening; Glen Kristiansen; Klaus Jung
[Tumor suppressor RECK in prostate carcinoma. Decreased RECK expression as indicator of proteolytic imbalance].
Der Urologe. Ausg. A 2007;46(9):1081-2.
2007: Monika Jung; Falk Ohl; Carsten Stephan; Anja Rabien; Glen Kristiansen; A Radonić; Stefan A Loening; Klaus Jung
[Quantifying gene expression in prostate carcinoma. Which endogenous reference genes are suitable?].
Der Urologe. Ausg. A 2007;46(9):1083-4.
2007: Michael Lein; Azizbek Ramankulov; Carsten Stephan; J Kramer; Stefan A Loening; Klaus Jung
[New serum markers of bone metastasis in prostate carcinoma].
Der Urologe. Ausg. A 2007;46(9):1087-8.
2007: Stefan Ludwig; Carsten Stephan; Michael Lein; Stefan A Loening; Klaus Jung
S100A8, S100A9, and the S100A8/A9 complex in circulating blood are not associated with prostate cancer risk-A re-evaluation study.
The Prostate 2007;67(12):1301-7.
2007: Anja Rabien; Glen Kristiansen; E P Diamandis; Klaus Jung; Carsten Stephan
[Human kallikreins as tumor markers. Validation of potential marker of prostate cancer in serum and tissue].
Der Urologe. Ausg. A 2007;46(9):1070-1.
2007: Azizbek Ramankulov; Michael Lein; Glen Kristiansen; Hellmuth-Alexander Meyer; Stefan A Loening; Klaus Jung
Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma.
Journal of cancer research and clinical oncology 2007;133(9):643-52.
2007: Carsten Stephan; Hellmuth-Alexander Meyer; Eva-Maria Paul; Glen Kristiansen; Stefan A Loening; Michael Lein; Klaus Jung
Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.
Anticancer research 2007;27(4A):1833-6.
2007: Carsten Stephan; Jürgen Kramer; Hellmuth-Alexander Meyer; Glen Kristiansen; Sabine Ziemer; Serdar Deger; Michael Lein; Stefan A Loening; Klaus Jung
Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
BJU international 2007;99(6):1427-31.
2007: Manfred Johannsen; Uwe Gneveckow; Kasra Taymoorian; Burghard Thiesen; Norbert Waldöfner; Regina Scholz; Klaus Jung; Andreas Jordan; Peter Wust; Stefan A Loening
Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2007;23(3):315-23.
2007: Susan Cottrell; Klaus Jung; Glen Kristiansen; Elke Eltze; Axel Semjonow; Michael Ittmann; Arndt Hartmann; Thomas A Stamey; Carolina Haefliger; Gunter Weiss
Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
The Journal of urology 2007;177(5):1753-8.
2007: Carsten Stephan; Hellmuth-Alexander Meyer; Henning Cammann; Michael Lein; Stefan A Loening; Klaus Jung
Re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 2007;51:1236-43.
European urology 2007;51(5):1446-7; author reply 1448.
2007: Anja Rabien; Mick Burkhardt; Monika Jung; Florian R Fritzsche; Martin Ringsdorf; Hanka Schicktanz; Stefan A Loening; Glen Kristiansen; Klaus Jung
Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
European urology 2007;51(5):1259-66.
2007: Carsten Stephan; Henning Cammann; Hellmuth-Alexander Meyer; Michael Lein; Klaus Jung
PSA and new biomarkers within multivariate models to improve early detection of prostate cancer.
Cancer letters 2007;249(1):18-29.
2007: Klaus Jung
Preanalytical biases in measurement of matrix metalloproteinases and their tissue inhibitors in peripheral blood.
The Journal of rheumatology 2007;34(4):890-2; author reply 892.
2007: Klaus Jung
Re: A molecular correlate to the Gleason grading system for prostate adenocarcinoma.
European urology 2007;51(3):851-2.
2007: Carsten Stephan; Chuanliang Xu; Henning Cammann; Markus Graefen; Alexander Haese; Hartwig Huland; Axel Semjonow; Eleftherios P Diamandis; Mesut Remzi; Bob Djavan; Mark F Wildhagen; Bert G Blijenberg; Patrik Finne; Ulf-Hakan Stenman; Klaus Jung; Hellmuth-Alexander Meyer
Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men.
World journal of urology 2007;25(1):95-103.
2007: Glòria Tabarés; Klaus Jung; Janett Reiche; Carsten Stephan; Michael Lein; Rosa Peracaula; Rafael de Llorens; Wolfgang Hoesel
Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples.
Clinical biochemistry 2007;40(5-6):343-50.
2007: Carsten Denkert; Andrea Thoma; Silvia Niesporek; Wilko Weichert; Ines Koch; Aurelia Noske; Hanka Schicktanz; Mick Burkhardt; Klaus Jung; Manfred Dietel; Glen Kristiansen
Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of Polo-like kinase-1.
The Prostate 2007;67(4):361-9.
2007: Azizbek Ramankulov; Michael Lein; Glen Kristiansen; Stefan A Loening; Klaus Jung
Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer.
The Prostate 2007;67(3):330-40.
2007: Klaus Jung; Wolfgang Hoesel; Janett Reiche; Serdar Deger; Jürgen Kramer; Stefan A Loening; Michael Lein; Carsten Stephan
Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
Urology 2007;69(2):320-5.
2007: Claudia Abramjuk; Michael Lein; Winfried Rothaug; Hans-Willi Krell; Stefan A Loening; Klaus Jung
Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model.
Cancer chemotherapy and pharmacology 2007;59(2):275-82.
2007: Monika Jung; Azizbek Ramankulov; Jan Roigas; Manfred Johannsen; Martin Ringsdorf; Glen Kristiansen; Klaus Jung
In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR.
BMC molecular biology 2007;8():47.
2007: Raquel F Gerlach; Caroline Demacq; Klaus Jung; Jose E Tanus-Santos
Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.
Clinical biochemistry 2007;40(1-2):119-23.
2006: Florian R Fritzsche; Monika Jung; Chuanliang Xu; Anja Rabien; Hanka Schicktanz; Carsten Stephan; Manfred Dietel; Klaus Jung; Glen Kristiansen
ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis.
Virchows Archiv : an international journal of pathology 2006;449(6):628-36.
2006: Michael Lein; Inna Stibane; Ramin Mansour; Claudia Hege; Jan Roigas; Andreas H Wille; Klaus Jung; Glen Kristiansen; Dietmar Schnorr; Stefan A Loening; Serdar Deger
Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charité Hospital Berlin, Campus Mitte.
European urology 2006;50(6):1278-82; discussion 1283-4.
2006: Carsten Stephan; Hellmuth-Alexander Meyer; Maciej Kwiatkowski; Franz Recker; Henning Cammann; Stefan A Loening; Klaus Jung; Michael Lein
A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
European urology 2006;50(5):1014-20.
2006: Klaus Jung; Raquel F Gerlach; Jose E Tanus-Santos
Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases.
Clinica chimica acta; international journal of clinical chemistry 2006;373(1-2):180-1; author reply 182.
2006: Klaus Jung; Michael Lein; Martin Ringsdorf; Jan Roigas; Dietmar Schnorr; Stefan A Loening; Andrea Staack
Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
The Journal of urology 2006;176(4 Pt 1):1326-31.
2006: Carsten Stephan; Hellmuth-Alexander Meyer; Henning Cammann; Terukazu Nakamura; Eleftherios P Diamandis; Klaus Jung
Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network.
Biological chemistry 2006;387(6):801-5.
2006: Falk Ohl; Monika Jung; Aleksandar Radonić; Markus Sachs; Stefan A Loening; Klaus Jung
Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer.
The Journal of urology 2006;175(5):1915-20.
2006: Venugopal Bhuvarahamurthy; Glen Kristiansen; Manfred Johannsen; Stefan A Loening; Dietmar Schnorr; Klaus Jung; Andrea Staack
In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Oncology reports 2006;15(5):1379-84.
2006: Carsten Stephan; Chuanliang Xu; David A Brown; Samuel N Breit; Anja Michael; Terukazu Nakamura; Eleftherios P Diamandis; Hellmuth Meyer; Henning Cammann; Klaus Jung
Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network.
The Prostate 2006;66(6):651-9.
2006: Klaus Jung
Impact of blood sampling on circulating tissue inhibitors of metalloproteinases.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(8):2648; author reply 2648-9.
2006: Klaus Jung; Michael Lein; Hermann Butz; Carsten Stephan; Stefan A Loening; Thomas Keller
New insights into the diagnostic accuracy of complexed and total prostate specific antigen using discordance analysis characteristics.
The Journal of urology 2006;175(4):1275-80.
2006: Isrid Sturm; C Stephan; Bernhard Gillissen; R Siebert; M Janz; Silke Radetzki; Klaus Jung; S Loening; Bernd Dörken; Peter Daniel
Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma.
Cell death and differentiation 2006;13(4):619-27.
2006: Carsten Stephan; Klaus Jung; Terukazu Nakamura; George M Yousef; Glen Kristiansen; Eleftherios P Diamandis
Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
International journal of urology : official journal of the Japanese Urological Association 2006;13(3):238-43.
2006: Florian R Fritzsche; Tserenchunt Gansukh; C A Borgoño; Mick Burkhardt; Stefan Pahl; Empar Mayordomo; Klaus-Jürgen Winzer; Wilko Weichert; Carsten Denkert; Klaus Jung; Carsten Stephan; Manfred Dietel; Eleftherios P Diamandis; Edgar Dahl; Glen Kristiansen
Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status.
British journal of cancer 2006;94(4):540-7.
2006: Andrea Staack; Steffen Badendieck; Dietmar Schnorr; Stefan A Loening; Klaus Jung
Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
BMC urology 2006;6():19.
2006: Klaus Jung
Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2006;44(4):500-2.
2006: David A Brown; Carsten Stephan; Robyn L Ward; Mathew Law; Mark Hunter; Asne R Bauskin; Janaki Amin; Klaus Jung; Eleftherios P Diamandis; Garret M Hampton; Pamela J Russell; Graham G Giles; Samuel N Breit
Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(1):89-96.
2006: Carsten Stephan; Moritz Klaas; Christian Müller; Dietmar Schnorr; Stefan A Loening; Klaus Jung
Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.
Clinical chemistry 2006;52(1):59-64.
2006: Manfred Johannsen; Burghard Thiesen; Uwe Gneveckow; Kasra Taymoorian; Norbert Waldöfner; Regina Scholz; Serdar Deger; Klaus Jung; Stefan A Loening; Andreas Jordan
Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer.
The Prostate 2006;66(1):97-104.
2005: Michael Lein; Axel Semjonow; Markus Graefen; Maciej Kwiatkowski; Claudia Abramjuk; Carsten Stephan; Alexander Haese; fianceeyi chun; Dietmar Schnorr; Stefan A Loening; Klaus Jung
A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.
The Journal of urology 2005;174(6):2150-3.
2005: Carsten Stephan; Dietmar Schnorr; Stefan A Loening; Klaus Jung
Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
European urology 2005;48(6):1059-60; author reply 1060-1.
2005: Falk Ohl; Monika Jung; Chuanliang Xu; Carsten Stephan; Anja Rabien; Mick Burkhardt; Andreas Nitsche; Glen Kristiansen; Stefan A Loening; Aleksandar Radonić; Klaus Jung
Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?
Journal of molecular medicine (Berlin, Germany) 2005;83(12):1014-24.
2005: Klaus Jung; Arielle Meisser; Paul Bischof
Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes.
International journal of cancer. Journal international du cancer 2005;116(6):1000-1; author reply 1002-3.
2005: Carsten Stephan; Klaus Jung; Antoninus Soosaipillai; George M Yousef; Henning Cammann; Hellmuth Meyer; Chuanliang Xu; Eleftherios P Diamandis
Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
BJU international 2005;96(4):521-7.
2005: Claudia Abramjuk; Klaus Jung; Hans-Willi Krell; Rolf Juchem; Robert Peters; Kasra Taymoorian; Andrea Staack; Carsten Stephan; Jörg Schnorr; Stefan A Loening; Michael Lein
Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats.
Anti-cancer drugs 2005;16(8):855-61.
2005: Venugopal Bhuvarahamurthy; Joerg Schroeder; Glen Kristiansen; Jan Roigas; Carsten Denkert; Manfred Johannsen; Michael Lein; Stefan A Loening; Dietmar Schnorr; Klaus Jung; Andrea Staack
Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Oncology reports 2005;14(3):777-82.
2005: Carsten Stephan; Greta Stroebel; Marc Heinau; Andre Lenz; Andreas Roemer; Michael Lein; Dietmar Schnorr; Stefan A Loening; Klaus Jung
The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Cancer 2005;104(5):993-1003.
2005: M John; Klaus Jung
Pre-analytical conditions for the assessment of circulating MMP-9 and TIMP-1: consideration of pitfalls.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2005;26(2):364-5; author reply 365-6.
2005: Manfred Johannsen; Burghard Thiesen; Andreas Jordan; Kasra Taymoorian; Uwe Gneveckow; Norbert Waldöfner; Regina Scholz; Martin Koch; Michael Lein; Klaus Jung; Stefan A Loening
Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model.
The Prostate 2005;64(3):283-92.
2005: Matthias John; Klaus Jung
Consideration of important preanalytical conditions for the assessment of circulating matrix metalloproteinase-9.
American journal of respiratory and critical care medicine 2005;172(2):254; author reply 254.
2005: Carsten Stephan; Henning Cammann; Klaus Jung
Artificial neural networks: has the time come for their use in prostate cancer patients?
Nature clinical practice. Urology 2005;2(6):262-3.
2005: Martina Geheeb; Anja Rabien; Falk Ohl; Monika Jung; Klaus Jung
Misinterpretation of quantitative RT-PCR results: A comment on the article by Ohashi et al. "RNA degradation in human breast tissue after surgical removal: a time course study", Exp. Mol. Pathol. 77 (2004) 98-103.
Experimental and molecular pathology 2005;78(3):263; author reply 264.
2005: Klaus Jung
Serum or plasma: what kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors?
Journal of neuroimmunology 2005;162(1-2):1-2.
2005: Klaus Jung
Consideration of preanalytical conditions to use circulating matrix metalloproteinases as diagnostic markers.
Transplantation 2005;79(6):744.
2005: Thomas Keller; Hermann Butz; Michael Lein; Maciej Kwiatkowski; Axel Semjonow; Hans-Joachim Luboldt; Peter Hammerer; Carsten Stephan; Klaus Jung
Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen.
Clinical chemistry 2005;51(3):532-9.
2005: Iacovos Michael; Lisa Kurlender; Nader Memari; George M Yousef; Daisy Du; Linda Grass; Carsten Stephan; Klaus Jung; Eleftherios P Diamandis
Intron retention: a common splicing event within the human kallikrein gene family.
Clinical chemistry 2005;51(3):506-15.
2005: Chuanliang Xu; Monika Jung; Mick Burkhardt; Carsten Stephan; Dietmar Schnorr; Stefan A Loening; Klaus Jung; Manfred Dietel; Glen Kristiansen
Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy.
The Prostate 2005;62(3):224-32.
2005: Klaus Jung
Careful attention to blood sampling as a preanalytical determinant of circulating matrix metalloproteinase 9 to avoid misinterpretations: comment on the article by Ainiala et al.
Arthritis and rheumatism 2005;52(2):673-4; author reply 674.
2005: Anja Michael; Carsten Stephan; Glen Kristiansen; Mick Burckhardt; Stefan A Loening; Dietmar Schnorr; Klaus Jung
Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
The Prostate 2005;62(1):34-9.
2004: Andreas Roemer; Lutz Schwettmann; Monika Jung; Carsten Stephan; Jan Roigas; Glen Kristiansen; Stefan A Loening; Ralf Lichtinghagen; Klaus Jung
The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers?
The Journal of urology 2004;172(6 Pt 1):2162-6.
2004: Klaus Jung; Janett Reiche; Axel Boehme; Carsten Stephan; Stefan A Loening; Dietmar Schnorr; Wolfgang Hoesel; Pranav Sinha
Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: potential to improve diagnosis of prostate cancer.
Clinical chemistry 2004;50(12):2292-301.
2004: Venugopal Bhuvarahamurthy; Joerg Schroeder; Carsten Denkert; Glen Kristiansen; Dietmar Schnorr; Stefan A Loening; Klaus Jung; Andrea Staack
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Oncology reports 2004;12(4):909-13.
2004: Klaus Jung; Michael Lein; Carsten Stephan; Katharina Von Hösslin; Axel Semjonow; Pranav Sinha; Stefan A Loening; Dietmar Schnorr
Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.
International journal of cancer. Journal international du cancer 2004;111(5):783-91.
2004: George M Yousef; Nicole M A White; Lisa Kurlender; Iacovos Michael; Nader Memari; John-Desmond Robb; Dionyssios Katsaros; Carsten Stephan; Klaus Jung; Eleftherios P Diamandis
The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2004;25(5-6):221-7.
2004: Wilko Weichert; Mathias Schmidt; Volker Gekeler; Carsten Denkert; Carsten Stephan; Klaus Jung; Stefan A Loening; Manfred Dietel; Glen Kristiansen
Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades.
The Prostate 2004;60(3):240-5.
2004: Manfred Johannsen; Andreas Jordan; Regina Scholz; Martin Koch; Michael Lein; Serdar Deger; Jan Roigas; Klaus Jung; Stefan A Loening
Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate cancer.
Journal of endourology / Endourological Society 2004;18(5):495-500.
2004: Andrea Staack; Diana Tolic; Glen Kristiansen; Dietmar Schnorr; Stefan A Loening; Klaus Jung
Expression of cathepsins B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder.
Urology 2004;63(6):1089-94.
2004: C Stephan; M Lein; D Schnorr; S A Loening; Klaus Jung
Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy.
BJU international 2004;93(9):1360-1.
2004: Lisa Kurlender; George M Yousef; Nader Memari; John-Desmond Robb; Iacovos Michael; Carla A Borgoño; Dionyssios Katsaros; Carsten Stephan; Klaus Jung; Eleftherios P Diamandis
Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2004;25(3):149-56.
2004: George M Yousef; Carla A Borgoño; Iacovos Michael; Christine Davidian; Carsten Stephan; Klaus Jung; Eleftherios P Diamandis
Molecular cloning of a new gene which is differentially expressed in breast and prostate cancers.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2004;25(3):122-33.
2004: Carsten Stephan; Klaus Jung; Henning Cammann
Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate-specific antigen levels < or = 10 ng/ml.
Cancer 2004;100(9):1989-90; author reply 1989-90.
2004: Klaus Jung; Carsten Stephan; Michaela Lewandowski; Silke Klotzek; Monika Jung; Glen Kristiansen; Michael Lein; Stefan A Loening; Dietmar Schnorr
Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer.
Cancer letters 2004;205(2):173-80.
2004: Anja Michael; Carsten Stephan; Dietmar Schnorr; Stefan A Loening; Klaus Jung
Serum macrophage migration inhibitory factor is not elevated in patients with prostate cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2004;13(2):328-9.
2004: Andreas Roemer; Lutz Schwettmann; Monika Jung; Jan Roigas; Glen Kristiansen; Dietmar Schnorr; Stefan A Loening; Klaus Jung; Ralf Lichtinghagen
Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome.
Oncology reports 2004;11(2):529-36.
2004: Glen Kristiansen; Christian Pilarsky; Janja Pervan; Burkard Stürzebecher; Carsten Stephan; Klaus Jung; Stefan A Loening; André Rosenthal; Manfred Dietel
CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer.
The Prostate 2004;58(2):183-92.
2004: Carsten Stephan; George M Yousef; Andreas Scorilas; Klaus Jung; Monika Jung; Glen Kristiansen; Steffen Hauptmann; Tadaaki Kishi; Terukazu Nakamura; Stefan A Loening; Eleftherios P Diamandis
Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.
The Journal of urology 2004;171(1):187-91.
2003: Klaus Jung; Carsten Stephan; Axel Semjonow; Michael Lein; Dietmar Schnorr; Stefan A Loening
Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
The Journal of urology 2003;170(6 Pt 1):2302-5.
2003: Jan Roigas; Serdar Deger; J Schroeder; Andreas H Wille; Ingolf Turk; Brigitte Brux; Klaus Jung; Dietmar Schnorr; Stefan A Loening
Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma.
Urological research 2003;31(6):358-62.
2003: Terukazu Nakamura; Andreas Scorilas; Carsten Stephan; Klaus Jung; Antoninus Soosaipillai; Eleftherios P Diamandis
The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia.
Cancer research 2003;63(19):6543-6.
2003: Michael Lein; Maciej Kwiatkowski; Axel Semjonow; Hans-Joachim Luboldt; Peter Hammerer; Carsten Stephan; Virgilijus Klevecka; Kasra Taymoorian; Dietmar Schnorr; Franz Recker; Stefan A Loening; Klaus Jung
A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations.
The Journal of urology 2003;170(4 Pt 1):1175-9.
2003: Carsten Stephan; B Vogel; Henning Cammann; Michael Lein; Virgilijus Klevecka; Pranav Sinha; Glen Kristiansen; Dietmar Schnorr; Klaus Jung; Stefan A Loening
[An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2-20 microg/l].
Der Urologe. Ausg. A 2003;42(9):1221-9.
2003: George M Yousef; Carsten Stephan; Andreas Scorilas; Mohamed Abd Ellatif; Klaus Jung; Glen Kristiansen; Monika Jung; Mary-Ellen Polymeris; Eleftherios P Diamandis
Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues.
The Prostate 2003;56(4):287-92.
2003: Monika Jung; Silke Klotzek; Michaela Lewandowski; Michael Fleischhacker; Klaus Jung
Changes in concentration of DNA in serum and plasma during storage of blood samples.
Clinical chemistry 2003;49(6 Pt 1):1028-9.
2003: Sebastian Wesseling; Carsten Stephan; Axel Semjonow; Michael Lein; Brigitte Brux; Pranav Sinha; Stefan A Loening; Klaus Jung
Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
Clinical chemistry 2003;49(6 Pt 1):887-94.
2003: Ralf Lichtinghagen; Petra B Musholt; Carsten Stephan; Michael Lein; Glen Kristiansen; Steffen Hauptmann; Birgit Rudolph; Dietmar Schnorr; Stefan A Loening; Klaus Jung
mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue.
Anticancer research 2003;23(3B):2617-24.
2003: Terukazu Nakamura; Carsten Stephan; Andreas Scorilas; George M Yousef; Klaus Jung; Eleftherios P Diamandis
Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues.
Urology 2003;61(5):1042-6.
2003: Monika Jung; Andreas Römer; Gernot Keyszer; Michael Lein; Glen Kristiansen; Dietmar Schnorr; Stefan A Loening; Klaus Jung
mRNA expression of the five membrane-type matrix metalloproteinases MT1-MT5 in human prostatic cell lines and their down-regulation in human malignant prostatic tissue.
The Prostate 2003;55(2):89-98.
2003: T Nakamura; Andreas Scorilas; C Stephan; George M Yousef; G Kristiansen; Klaus Jung; Eleftherios P Diamandis
Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues.
British journal of cancer 2003;88(7):1101-4.
2003: Carsten Stephan; Sebastian Wesseling; Tania Schink; Klaus Jung
Comparison of eight computer programs for receiver-operating characteristic analysis.
Clinical chemistry 2003;49(3):433-9.
2003: Klaus Jung; Hans-Willi Krell; Bernhard Ortel; Tayyaba Hasan; Andreas Römer; Dietmar Schnorr; Stefan A Loening; Michael Lein
Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats.
The Prostate 2003;54(3):206-11.
2003: Carsten Stephan; George M Yousef; Andreas Scorilas; Klaus Jung; Monika Jung; Glen Kristiansen; Steffen Hauptmann; Bhupinder S Bharaj; Terukazu Nakamura; Stefan A Loening; Eleftherios P Diamandis
Quantitative analysis of kallikrein 15 gene expression in prostate tissue.
The Journal of urology 2003;169(1):361-4.
2002: E Baumgart; Severin Lenk; Stefan A Loening; Klaus Jung
Tissue inhibitors of metalloproteinases 1 and 2 in human seminal plasma and their association with spermatozoa.
International journal of andrology 2002;25(6):369-71.
2002: E Baumgart; Severin Lenk; Stefan A Loening; Klaus Jung
Quantitative differences in matrix metalloproteinase (MMP)-2, but not in MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1 or TIMP-2, in seminal plasma of normozoospermic and azoospermic patients.
Human reproduction (Oxford, England) 2002;17(11):2919-23.
2002: George M Yousef; Christina V Obiezu; Klaus Jung; Carsten Stephan; Andreas Scorilas; Eleftherios P Diamandis
Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues.
Urology 2002;60(4):714-8.
2002: Ralf Lichtinghagen; Petra B Musholt; Michael Lein; Andreas Römer; Birgit Rudolph; Glen Kristiansen; Steffen Hauptmann; Dietmar Schnorr; Stefan A Loening; Klaus Jung
Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue.
European urology 2002;42(4):398-406.
2002: Klaus Jung; Michael Lein; Ardreas Roemer; Ralf Lichtinghagen
Circulating gelatinase B (MMP-9)--the impact of the preanalytical step of blood collection.
Matrix biology : journal of the International Society for Matrix Biology 2002;21(5):381-2.
2002: Carsten Stephan; Henning Cammann; Axel Semjonow; Eleftherios P Diamandis; Leon F A Wymenga; Michael Lein; Pranav Sinha; Stefan A Loening; Klaus Jung
Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies.
Clinical chemistry 2002;48(8):1279-87.
2002: Christina V Obiezu; Antoninus Soosaipillai; Klaus Jung; Carsten Stephan; Andreas Scorilas; David H C Howarth; Eleftherios P Diamandis
Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry.
Clinical chemistry 2002;48(8):1232-40.
2002: Klaus Jung; Michael Lein; K v Hösslin; A Grosse; S Roth; K Possinger; D Lüftner
Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults.
The International journal of biological markers 2002;17(3):177-81.
2002: D Mangoldt; B Sinn; Michael Lein; Hans-Willi Krell; Dietmar Schnorr; Stefan A Loening; Klaus Jung
The novel synthetic inhibitor of matrix metalloproteinases Ro 28-2653 induces apoptosis in Dunning tumor cells.
Apoptosis : an international journal on programmed cell death 2002;7(3):217-20.
2002: Carsten Stephan; Klaus Jung; Henning Cammann; Birgit Vogel; Brigitte Brux; Glen Kristiansen; Birgit Rudolph; Steffen Hauptmann; Michael Lein; Dietmar Schnorr; Pranav Sinha; Stefan A Loening
An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: results of a 5-year investigation.
International journal of cancer. Journal international du cancer 2002;99(3):466-73.
2002: Guido Filler; Friedrich Priem; Nathalie Lepage; Pranav Sinha; Ilka Vollmer; Heather Clark; Erin Keely; Mary Matzinger; Ayub Akbari; Harald Althaus; Klaus Jung
Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children.
Clinical chemistry 2002;48(5):729-36.
2002: George M Yousef; Andreas Scorilas; Albert Chang; Laura Rendl; Maria Diamandis; Klaus Jung; Eleftherios P Diamandis
Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues.
The Prostate 2002;51(2):126-32.
2002: Bhupinder B Bharaj; Liu-Ying Luo; Klaus Jung; Carsten Stephan; Eleftherios P Diamandis
Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers.
The Prostate 2002;51(1):35-41.
2002: Michael Lein; Klaus Jung; Bernhard Ortel; Carsten Stephan; Winfried Rothaug; Rolf Juchem; Manfred Johannsen; Serdar Deger; Dietmar Schnorr; Stefan A Loening; Hans-Willi Krell
The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model.
Oncogene 2002;21(13):2089-96.
2002: M John; U Oltmanns; C Witt; Klaus Jung
Re: Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer (Respir Med 2001; 95: 1-4).
Respiratory medicine 2002;96(2):126-9.
2002: Andrea Staack; Frank Koenig; Dmitry I Daniltchenko; Steffen Hauptmann; Stefan A Loening; Dietmar Schnorr; Klaus Jung
Cathepsins B, H, and L activities in urine of patients with transitional cell carcinoma of the bladder.
Urology 2002;59(2):308-12.
2002: Carsten Stephan; Klaus Jung; Eleftherios P Diamandis; Harry G Rittenhouse; Michael Lein; Stefan A Loening
Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer.
Urology 2002;59(1):2-8.
2002: Matthias John; Ute Oltmanns; Ingo Fietze; Christian Witt; Klaus Jung
Increased production of matrix metalloproteinase-2 in alveolar macrophages and regulation by interleukin-10 in patients with acute pulmonary sarcoidosis.
Experimental lung research 2002;28(1):55-68.
2002: Ju Zhang; Klaus Jung; Michael Lein; Glen Kristiansen; Birgit Rudolph; Steffen Hauptmann; Dietmar Schnorr; Stefan A Loening; Ralf Lichtinghagen
Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines.
The Prostate 2002;50(1):38-45.
2002: C Stephan; Klaus Jung; D Schnorr; M Lein; P Sinha; S A Loening
Re: a prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. I.D.C. Mitchell, B.L. Croal, A. Dickie, N.P. Cohen and I. Ross. J Urol, 165: 1549-1553, 2001.
The Journal of urology 2002;167(1):259-60.
2001: Friedrich Priem; Harald Althaus; Klaus Jung; Pranav Sinha
Beta-trace protein is not better than cystatin C as an indicator of reduced glomerular filtration rate.
Clinical chemistry 2001;47(12):2181.
2001: Klaus Jung; Michael Lein; C Laube; Ralf Lichtinghagen
Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood.
Clinica chimica acta; international journal of clinical chemistry 2001;314(1-2):241-4.
2001: Klaus Jung; Michael Lein; K von Hösslin; Brigitte Brux; Dietmar Schnorr; Stefan A Loening; Pranav Sinha
Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer.
Clinical chemistry 2001;47(11):2061-3.
2001: Albert Chang; George M Yousef; Klaus Jung; E Rajpert-De Meyts; Eleftherios P Diamandis
Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: differential expression in the human testis and testicular cancer.
Anticancer research 2001;21(5):3147-52.
2001: Jan Roigas; Gert Schulze; S Raytarowski; Klaus Jung; Dietmar Schnorr; Stefan A Loening
Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2001;22(5):282-5.
2001: Klaus Jung; Carsten Stephan; U Elgeti; Michael Lein; Brigitte Brux; Glen Kristiansen; Birgit Rudolph; Steffen Hauptmann; Dietmar Schnorr; Stefan A Loening; Pranav Sinha
Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
International journal of cancer. Journal international du cancer 2001;93(5):759-65.
2001: Michael Sidiropoulos; Albert Chang; Klaus Jung; Eleftherios P Diamandis
Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer.
British journal of cancer 2001;85(3):393-7.
2001: Liu-Ying Luo; E R Rajpert-De Meyts; Klaus Jung; Eleftherios P Diamandis
Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue.
British journal of cancer 2001;85(2):220-4.
2001: Andreas Scorilas; George M Yousef; Klaus Jung; E Rajpert-De Meyts; S Carsten; Eleftherios P Diamandis
Identification and characterization of a novel human testis-specific kinase substrate gene which is downregulated in testicular tumors.
Biochemical and biophysical research communications 2001;285(2):400-8.
2001: George M Yousef; Maria Diamandis; Klaus Jung; Eleftherios P Diamandis
Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis.
Genomics 2001;74(3):385-95.
2001: Michael Lein; Klaus Jung; Peter Hammerer; M Graefen; Axel Semjonow; P Stieber; M Ossendorf; Hans-Joachim Luboldt; Brigitte Brux; Carsten Stephan; Dietmar Schnorr; Stefan A Loening
A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
The Prostate 2001;47(2):77-84.
2001: George M Yousef; Angeliki Magklara; Albert Chang; Klaus Jung; Dionyssios Katsaros; Eleftherios P Diamandis
Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies.
Cancer research 2001;61(8):3425-31.
2001: S Gerhards; Klaus Jung; Frank Koenig; Dmitry I Daniltchenko; Steffen Hauptmann; Dietmar Schnorr; Stefan A Loening
Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma.
Urology 2001;57(4):675-9.
2001: Klaus Jung; Carsten Stephan; Michael Lein; Brigitte Brux; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms--What has to be considered?
The Prostate 2001;46(4):307-10.
2001: Monika Jung; J Marcus Muche; Ansgar Lukowsky; Klaus Jung; Stefan A Loening
Dimethyl sulfoxide as additive in ready-to-use reaction mixtures for real-time polymerase chain reaction analysis with SYBR Green I dye.
Analytical biochemistry 2001;289(2):292-5.
2001: S Gerhards; Klaus Jung; Frank Koenig; Dmitry I Daniltchenko; S Hauptmann; D Schnorr; S A Loening
Correspondence re: C. F. M. Sier et al., Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res., 6: 2333-2340, 2000.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(2):445-7.
2001: George M Yousef; Andreas Scorilas; Klaus Jung; Linda K Ashworth; Eleftherios P Diamandis
Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer.
The Journal of biological chemistry 2001;276(1):53-61.
2001: Michael Lein; Klaus Jung; U Elgeti; T Petras; Carsten Stephan; Brigitte Brux; Pranav Sinha; Björn Winkelmann; Dietmar Schnorr; Stefan A Loening
Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
European urology 2001;39(1):57-64.
2000: Klaus Jung; Michael Lein; Brigitte Brux; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2000;38(12):1271-5.
2000: Michael Lein; Klaus Jung; U Elgeti; Brigitte Brux; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
Anticancer research 2000;20(6D):4997-5001.
2000: C Stephan; Klaus Jung; M Lein; D Schnorr; S A Loening
Re: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
The Journal of urology 2000;164(5):1671-2.
2000: Jan Roigas; Gert Schulze; S Raytarowski; Klaus Jung; Dietmar Schnorr; Stefan A Loening
[Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
Der Urologe. Ausg. A 2000;39(6):554-6.
2000: Carsten Stephan; Klaus Jung; Michael Lein; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2000;9(11):1133-47.
2000: Angeliki Magklara; Andreas Scorilas; Carsten Stephan; G O Kristiansen; S Hauptmann; Klaus Jung; Eleftherios P Diamandis
Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue.
Urology 2000;56(3):527-32.
2000: M Lein; C Stephan; Klaus Jung; D Schnorr; Stefan A Loening
[Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis].
Der Urologe. Ausg. A 2000;39(4):313-23.
2000: M Lein; F Koenig; Joseph Misdraji; W Scott McDougal; Klaus Jung; S A Loening; Tayyaba Hasan; Bernhard Ortel
Laser-induced hyperthermia in rat prostate cancer: role of site of tumor implantation.
Urology 2000;56(1):167-72.
2000: M Jung; J M Muche; Klaus Jung; S A Loening
Methods in molecular biology: minor errors in primer citations with major consequences: how can we minimize these mistakes?
British journal of cancer 2000;82(9):1611-2; author reply 1612-3.
2000: M Lein; Klaus Jung; D K Le; T Hasan; B Ortel; D Borchert; B Winkelmann; Dietmar Schnorr; S A Loenings
Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model.
The Prostate 2000;43(2):77-82.
2000: Carsten Stephan; Klaus Jung; Brigitte Brux; Michael Lein; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
Elimination of serum complexed prostate-specific antigen after radical retropubic prostatectomy.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2000;38(4):309-11.
2000: Carsten Stephan; Klaus Jung; Brigitte Brux; Michael Lein; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation.
Urology 2000;55(4):560-3.
2000: Michael Lein; Klaus Jung; C Laube; T Hübner; B Winkelmann; Carsten Stephan; Steffen Hauptmann; Birgit Rudolph; Dietmar Schnorr; Stefan A Loening
Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma.
International journal of cancer. Journal international du cancer 2000;85(6):801-4.
2000: Klaus Jung; U Elgeti; Michael Lein; Brigitte Brux; Pranav Sinha; Birgit Rudolph; Steffen Hauptmann; Dietmar Schnorr; Stefan A Loening
Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Clinical chemistry 2000;46(1):55-62.
2000: Klaus Jung; Brigitte Brux; Michael Lein; Birgit Rudolph; Glen Kristiansen; Steffen Hauptmann; Dietmar Schnorr; Stefan A Loening; Pranav Sinha
Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.
Clinical chemistry 2000;46(1):47-54.
1999: G Hampel; R Hosseini; Klaus Jung
Different effects of cyclosporine and tacrolimus on the activation of mesangial metalloproteinases and their inhibitors.
Transplantation proceedings 1999;31(7):2757-8.
1999: Guido Filler; Friedrich Priem; Ilka Vollmer; J Gellermann; Klaus Jung
Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate.
Pediatric nephrology (Berlin, Germany) 1999;13(6):501-5.
1999: Michael Lein; Klaus Jung; Brigitte Brux; A Knäbich; P Sinha; Dietmar Schnorr; Stefan A Loening
Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
The Journal of urology 1999;162(2):502-3.
1999: Michael Lein; L Nowak; Klaus Jung; C Laube; N Ulbricht; Dietmar Schnorr; Stefan A Loening
Metalloproteinases and tissue inhibitors of matrix-metalloproteinases in plasma of patients with prostate cancer and in prostate cancer tissue.
Annals of the New York Academy of Sciences 1999;878():544-6.
1999: Michael Lein; Klaus Jung; L Nowak; Dietmar Schnorr; Stefan A Loening
Analytical aspects regarding the measurement of metalloproteinases.
Annals of the New York Academy of Sciences 1999;878():491-3.
1999: Klaus Jung; Brigitte Brux; Michael Lein; A Knäbich; Pranav Sinha; Birgit Rudolph; Dietmar Schnorr; Stefan A Loening
Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Urology 1999;53(6):1160-7; discussion 1167-8.
1999: Friedrich Priem; Harald Althaus; M Birnbaum; Pranav Sinha; H S Conradt; Klaus Jung
Beta-trace protein in serum: a new marker of glomerular filtration rate in the creatinine-blind range.
Clinical chemistry 1999;45(4):567-8.
1999: Klaus Jung; Brigitte Brux; A Knäbich; Michael Lein; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus alpha1-antichymotrypsin-prostate- specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia.
Clinical chemistry 1999;45(3):422-4.
1999: Gernot Keyszer; I Lambiri; R Nagel; C Keysser; M Keysser; E Gromnica-Ihle; Juliane K Franz; Gerd R Burmester; Klaus Jung
Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
The Journal of rheumatology 1999;26(2):251-8.
1999: B Friedrich; Klaus Jung; Michael Lein; Ingolf Türk; Birgit Rudolph; G Hampel; Dietmar Schnorr; Stefan A Loening
Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue.
European journal of cancer (Oxford, England : 1990) 1999;35(1):138-44.
1999: T Petras; W Siems; W Henke; Klaus Jung; CJ Olbricht; Wilfried Gwinner; T Grune
Metabolic rates of 4-hydroxynonenal in tubular and mesangial cells of the kidney.
Experimental nephrology 1999;7(1):59-62.
1999: Klaus Jung; J Zachow; Michael Lein; Brigitte Brux; Pranav Sinha; Severin Lenk; Dietmar Schnorr; Stefan A Loening
Rapid detection of elevated prostate-specific antigen levels in blood: performance of various membrane strip tests compared.
Urology 1999;53(1):155-60.
1998: Gernot Keyszer; I Lambiri; M Keysser; C Keysser; R Nagel; Gerd R Burmester; Klaus Jung
Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity.
Zeitschrift für Rheumatologie 1998;57(6):392-8.
1998: Klaus Jung; C Laube; Michael Lein; Ingolf Türk; Ralf Lichtinghagen; Birgit Rudolph; Dietmar Schnorr; Stefan A Loening
Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer.
International journal of cancer. Journal international du cancer 1998;78(3):392-3.
1998: M Lein; F Koenig; Klaus Jung; Francis J McGovern; Steven J Skates; D Schnorr; S A Loening
The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men.
British journal of urology 1998;82(2):231-6.
1998: Michael Lein; L Nowak; Klaus Jung; Frank Koenig; Dietmar Schnorr; Stefan A Loening
[Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma].
Der Urologe. Ausg. A 1998;37(4):377-81.
1998: Klaus Jung; C Laube; Michael Lein; Ralf Lichtinghagen; H Tschesche; Dietmar Schnorr; Stefan A Loening
Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood.
Clinical chemistry 1998;44(5):1060-2.
1998: Klaus Jung; A Meyer; Michael Lein; B Rudolph; Dietmar Schnorr; Stefan A Loening
Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate.
The Journal of urology 1998;159(5):1595-8.
1998: W Henke; T Hagen; Klaus Jung; S A Loening
Periodate-oxidized ATP stimulates the permeability transition of rat liver mitochondria.
Biochimica et biophysica acta 1998;1363(3):209-16.
1998: Klaus Jung; P von Klinggräff; Brigitte Brux; Pranav Sinha; Dietmar Schnorr; Stefan A Loening
Preanalytical determinants of total and free prostate-specific antigen and their ratio: blood collection and storage conditions.
Clinical chemistry 1998;44(3):685-8.
1998: Klaus Jung; Michael Lein; N Ulbrich; Birgit Rudolph; W Henke; Dietmar Schnorr; Stefan A Loening
Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: analytical aspects.
The Prostate 1998;34(2):130-6.
1998: Klaus Jung; B Friedrich; Ingolf Türk; Jan Roigas; M Lein; D Schnorr; S A Loening
Cathepsins B, H, L and cysteine proteinase inhibitors in renal cell carcinoma: no evidence for dysregulated proteolytic balance.
Journal of cancer research and clinical oncology 1998;124(1):60-1.
1998: Michael Lein; C Stephan; Klaus Jung; Dietmar Schnorr; S Loening
Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used?
Cancer investigation 1998;16(1):45-9.
1997: A Meyer; Klaus Jung; Michael Lein; Birgit Rudolph; Dietmar Schnorr; Stefan A Loening
Factors influencing the ratio of free to total prostate-specific antigen in serum.
International journal of cancer. Journal international du cancer 1997;74(6):630-6.
1997: Annekathrin Haberland; W Henke; T Grune; W Siems; Klaus Jung; Ingolf Schimke
Differential response of oxygen radical metabolism in rat heart, liver and kidney to cyclosporine A treatment.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 1997;46(11):452-4.
1997: W Henke; K Herdel; Klaus Jung; D Schnorr; S A Loening
Betaine improves the PCR amplification of GC-rich DNA sequences.
Nucleic acids research 1997;25(19):3957-8.
1997: Klaus Jung
Plasma but not serum should be used for determining tissue inhibitor of metalloproteinase in blood.
Alcoholism, clinical and experimental research 1997;21(6):1155-6.
1997: Michael Lein; L Nowak; Klaus Jung; Frank Koenig; Ralf Lichtinghagen; Dietmar Schnorr; Stefan A Loening
Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood.
Clinical biochemistry 1997;30(6):491-6.
1997: Michael Lein; Brigitte Brux; Klaus Jung; W Henke; F Koenig; C Stephan; Dietmar Schnorr; Stefan A Loening
Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1997;35(8):591-5.
1997: Guido Filler; I Witt; Friedrich Priem; Jochen H H Ehrich; Klaus Jung
Are cystatin C and beta 2-microglobulin better markers than serum creatinine for prediction of a normal glomerular filtration rate in pediatric subjects?
Clinical chemistry 1997;43(6 Pt 1):1077-8.
1997: Michael Lein; Klaus Jung; S Weiss; Dietmar Schnorr; S A Loening
Soluble CD44 variants in the serum of patients with urological malignancies.
Oncology 1997;54(3):226-30.
1997: Klaus Jung; L Nowak; Michael Lein; F Priem; Dietmar Schnorr; Stefan A Loening
Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.
International journal of cancer. Journal international du cancer 1997;74(2):220-3.
1997: C Stephan; Michael Lein; Klaus Jung; Dietmar Schnorr; Stefan A Loening
Re: Editorial: can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?
The Journal of urology 1997;157(4):1371.
1997: W Henke; M Jung; Klaus Jung; Michael Lein; H Schlechte; C Berndt; Birgit Rudolph; Dietmar Schnorr; Stefan A Loening
Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood.
International journal of cancer. Journal international du cancer 1997;70(1):52-6.
1997: Klaus Jung; B Seidel; Birgit Rudolph; Michael Lein; M V Cronauer; W Henke; G Hampel; Dietmar Schnorr; Stefan A Loening
Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells.
Free radical biology & medicine 1997;23(1):127-33.
1997: Carsten Stephan; Michael Lein; Klaus Jung; Dietmar Schnorr; Stefan A Loening
The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
Cancer 1997;79(1):104-9.
1996: Klaus Jung; L Nowak; Michael Lein; W Henke; Dietmar Schnorr; Stefan A Loening
Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood.
Clinical chemistry 1996;42(12):2043-5.
1996: Klaus Jung; W Henke; Michael Lein; Dietmar Schnorr; S A Loening
Polymerase chain reaction in the detection of micrometastases and circulating tumor cells.
Cancer 1996;78(11):2445-8.
1996: Michael Lein; S Weiss; Klaus Jung; Dietmar Schnorr; S Loening
Soluble CD44 variants in serum of patients with prostate cancer and other urological malignancies.
The Prostate 1996;29(5):334-5.
1996: Klaus Jung; L Nowak; Michael Lein; W Henke; Dietmar Schnorr; Stefan A Loening
What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood?
Clinica chimica acta; international journal of clinical chemistry 1996;254(1):97-100.
1996: W Henke; C Cetinsoy; Klaus Jung; S Loening
Non-hyperbolic calcium calibration curve of Fura-2: implications for the reliability of quantitative Ca2+ measurements.
Cell calcium 1996;20(3):287-92.
1996: W Henke; M Jung; Klaus Jung; Michael Lein; Horst H Schlechte; C Berndt; B Rudolph; Dietmar Schnorr; Stefan A Loening
Detection of PSA mRNA in blood by RT-PCR does not exclusively indicate prostatic tumor cells.
Clinical chemistry 1996;42(9):1499-500.
1996: C Stephan; Klaus Jung; Michael Lein; Dietmar Schnorr; Stefan A Loening
The ratio of free to total prostate-specific antigen in serum is correlated to the prostate volume.
International journal of cancer. Journal international du cancer 1996;67(3):461-2.
1996: Klaus Jung; Michael Lein; W Henke; Dietmar Schnorr; S A Loening
Isoforms of prostate-specific antigen in serum: a result of the glycosylation process in dysplastic prostatic cells?
The Prostate 1996;29(1):65-6.
1996: Klaus Jung; C Stephan; Michael Lein; W Henke; Dietmar Schnorr; Brigitte Brux; P Schürenkämper; Stefan A Loening
Analytical performance and clinical validity of two free prostate-specific antigen assays compared.
Clinical chemistry 1996;42(7):1026-33.
1996: Michael Lein; Klaus Jung; Dietmar Schnorr; W Henke; Stefan A Loening
Strip test for the quick detection of increased concentrations of prostate-specific antigen in blood.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1996;34(6):511-4.
1996: Klaus Jung
Pyridoxal-5' -phosphate stimulation of aminotransferase activities in serum of hemodialysis patients and renal-transplant recipients.
Clinical nephrology 1996;45(6):416-7.
1996: Klaus Jung; Michael Lein; Dietmar Schnorr; Brigitte Brux; W Henke; S Loening
Comparison between equimolar- and skewed-response assays of prostate specific antigen: is there an influence on the clinical significance when measuring total serum prostate specific antigen?
Annals of clinical biochemistry 1996;33 ( Pt 3)():209-14.
1996: Klaus Jung; Michael Lein; S Weiss; Dietmar Schnorr; W Henke; S Loening
Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia.
European journal of cancer (Oxford, England : 1990) 1996;32A(4):627-30.
1996: Klaus Jung; W Henke
Developmental changes of antioxidant enzymes in kidney and liver from rats.
Free radical biology & medicine 1996;20(4):613-7.
1995: Michael Lein; Klaus Jung; Dietmar Schnorr; W Henke; Brigitte Brux; Stefan A Loening
Rapid screening of PSA: evaluation of an immunochemical membrane strip test.
Clinical chemistry 1995;41(10):1545-7.
1995: Klaus Jung; A Scheifler; B D Schulze; M Scholz
Lower serum high-density lipoprotein-cholesterol concentration in patients undergoing maintenance hemodialysis with acetate than with bicarbonate.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1995;25(4):584-8.
1995: W Henke; Klaus Jung; F Polster
Effects of preservation solutions on cortical and medullary mitochondria of rat kidney.
Cellular and molecular biology (Noisy-le-Grand, France) 1995;41(2):319-26.
1995: Klaus Jung; M Jung
Cystatin C: a promising marker of glomerular filtration rate to replace creatinine.
Nephron 1995;70(3):370-1.
1994: Lüder M Fels; I Bundschuh; Wilfried Gwinner; Klaus Jung; M Pergande; H J Graubaum; Robert Graham Price; S A Taylor; Marc E De Broe; Guy NUYTS
Early urinary markers of target nephron segments as studied in cadmium toxicity.
Kidney international. Supplement 1994;47():S81-8.
1994: Klaus Jung
Urinary enzymes and low molecular weight proteins as markers of tubular dysfunction.
Kidney international. Supplement 1994;47():S29-33.
1994: Lüder M Fels; C Herbort; M Pergande; Klaus Jung; G Hotter; J Roselló; Emilio Gelpi; Antonio Mutti; Marc E De Broe; Hilmar Stolte
Nephron target sites in chronic exposure to lead.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1994;9(12):1740-6.
1994: M Pergande; Klaus Jung; S Precht; Lüder M Fels; C Herbort; Hilmar Stolte
Changed excretion of urinary proteins and enzymes by chronic exposure to lead.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1994;9(6):613-8.
1993: Klaus Jung; M Pergande; F Priem; S Becker; S Klotzek
Rapid screening of low molecular mass proteinuria: evaluation of the first immunochemical test strip for the detection of alpha 1-microglobulin in urine.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1993;31(10):683-7.
1993: M Pergande; Klaus Jung
Sandwich enzyme immunoassay of cystatin C in serum with commercially available antibodies.
Clinical chemistry 1993;39(9):1885-90.
1993: Klaus Jung; F Priem
What are the criteria to introduce new methods for determination of urinary N-acetyl-beta-D-glucosaminidase activity?
Annals of clinical biochemistry 1993;30 ( Pt 5)():501-4.
1993: W Henke; Klaus Jung
Comparison of the effects of the immunosuppressive agents FK 506 and cyclosporin A on rat kidney mitochondria.
Biochemical pharmacology 1993;46(5):829-32.
1993: Klaus Jung; P Kirschner; Andreas H Wille; G Brien
Excretion of urinary enzymes after extracorporeal shock wave lithotripsy: a critical reevaluation.
The Journal of urology 1993;149(6):1409-13.
1993: Klaus Jung; M Pergande; H J Graubaum; Lüder M Fels; U Endl; Hilmar Stolte
Urinary proteins and enzymes as early indicators of renal dysfunction in chronic exposure to cadmium.
Clinical chemistry 1993;39(5):757-65.
1993: I Bundschuh; C Herbort; Lüder M Fels; Klaus Jung; H J Graubaum; Hilmar Stolte
Renal fibronectin excretion as a marker for renal environmental toxins.
Contributions to nephrology 1993;101():177-84.
1993: Klaus Jung; S Kühler; S Klotzek; S Becker; W Henke
Effect of storage temperature on the activity of superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione S-transferase in rat liver and kidney homogenates.
Enzyme & protein 1993;47(3):149-55.
1992: K Müller; Werner G Siems; Tilman Grune; H David; W Henke; Klaus Jung
Adaptational increase of liver glutathione content during long-term application of cyclosporine A may attenuate toxic side effects.
Cellular and molecular biology (Noisy-le-Grand, France) 1992;38(7):729-38.
1992: Klaus Jung; M Pergande; G Schreiber; W Thierfelder
Reference intervals for alpha 1-microglobulin in urine.
Clinica chimica acta; international journal of clinical chemistry 1992;206(3):245-7.
1992: W Henke; E Nickel; Klaus Jung
Cyclosporine A inhibits ATP net uptake of rat kidney mitochondria.
Biochemical pharmacology 1992;43(5):1021-4.
1992: Klaus Jung; W Henke; B D Schulze; K Sydow; K Precht; S Klotzek
Practical approach for determining glomerular filtration rate by single-injection inulin clearance.
Clinical chemistry 1992;38(3):403-7.
1992: Klaus Jung; M Pergande
Sex- and age-dependent reference values of alpha-1-microglobulin in urine.
Nephron 1992;62(4):474-5.
1991: Klaus Jung; F Priem
A practical new assay for determining N-acetyl-beta-D-glucosaminidase activity in urine.
Clinica chimica acta; international journal of clinical chemistry 1991;203(2-3):405-7.
1991: Klaus Jung
Enzyme activities in urine: how should we express their excretion? A critical literature review.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1991;29(11):725-9.
1991: W Henke; Klaus Jung
Ischemia decreases the content of the adenine nucleotide translocator in mitochondria of rat kidney.
Biochimica et biophysica acta 1991;1056(1):71-5.
1991: Klaus Jung; S Klotzek
[Determination of kallikrein in gel-filtered urine using the chromogenic substrate D-valyl-L-leucyl-L-arginyl-4-nitroanilide].
Zeitschrift für medizinische Laboratoriumsdiagnostik 1991;32(2):116-7.
1991: Klaus Jung; S Klotzek; B D Schulze
[Evaluation of methods for the analysis of low insulin concentrations in serum].
Zeitschrift für medizinische Laboratoriumsdiagnostik 1991;32(1):23-9.
1991: Klaus Jung; F Priem; Hilmar Stolte; H J Graubaum; G May
[Excretion of beta-N-acetylglucosaminidase in urine of patients with kidney transplants and workers exposed to cadmium].
Wiener klinische Wochenschrift. Supplementum 1991;189():56-9.
1991: Klaus Jung; F Priem; G Klein
[A new kinetic method for measuring beta-N-acetylglucosaminidase activity in urine].
Wiener klinische Wochenschrift. Supplementum 1991;189():39-44.
1991: Klaus Jung; F Priem; S Klotzek; S Becker; W Henke
Methods compared for determining activity of N-acetyl-beta-D-glucosaminidase in urine without pretreatment of sample: different sensitivity and species effect.
Enzyme 1991;45(4):215-21.
1991: Klaus Jung; F Priem; W Henke; S Klotzek; S Becker
Evaluation of methods for determining N-acetyl-beta-D-glucosaminidase in urine of rats without purification of urine samples.
Journal of experimental animal science 1991;34(4):147-52.
1991: W Henke; M Ziegler; Wolfgang Dubiel; Klaus Jung
Mechanisms accounting for changes of adenine nucleotide content in mitochondria at ischemia.
Advances in experimental medicine and biology 1991;309A():309-12.
1991: Klaus Jung; W Henke; B D Schulze; K Sydow; K Precht; S Klotzek
Single-injection inulin clearance using only one blood sample as a suitable procedure to measure glomerular filtration rate.
Nephron 1991;59(4):694-5.
1991: Klaus Jung; S Becker
Multiple forms of N-acetyl-beta-D-glucosaminidase of human urine: isolation, properties and the development of a practical approach of differentiation.
Biomedica biochimica acta 1991;50(7):861-7.
1990: T Porstmann; H Schmechta; C Hentschel; H Doepel; P Pas; J Becker; M Pergande; Klaus Jung; E Nugel
Development of an immunoenzymometric assay for alpha 1-microglobulin and measurement of its serum concentration in normal and HIV-infected persons.
Journal of clinical chemistry and clinical biochemistry. Zeitschrift für klinische Chemie und klinische Biochemie 1990;28(10):669-75.